Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 4/20 | 0.35 |
| ▸ | PLK1 | P53350 | 4/20 | 0.35 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 2/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.31 |
| ▸ | MAOA | P21397 | 1/20 | 0.31 |
| ▸ | HTR2B | P41595 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | KDR | P35968 | 1/20 | 0.31 |
| ▸ | MAP3K8 | P41279 | 2/20 | 0.31 |
| ▸ | CDK2 | P24941 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4258682 | 1.00 | IGF1R (0.35) | IGF1RPLK1ADRB2ADRB1CYP2D6 | |
| SCHEMBL2200557 | 1.00 | IGF1R (0.35) | IGF1RPLK1ADRB2ADRB1CYP2D6 | |
| SCHEMBL2197154 | 1.00 | IGF1R (0.35) | IGF1RPLK1ADRB2ADRB1CYP2D6 | |
| SCHEMBL2198544 | 0.91 | PLK1 (0.35) | IGF1RPLK1HTR1AADRA2AADRA2B | |
| SCHEMBL2198979 | 0.90 | IGF1R (0.38) | IGF1RADRB2ADRB1CYP2D6NFKB1 | |
| SCHEMBL2196563 | 0.90 | PLK1 (0.34) | IGF1RPLK1HTR1AADRA2AADRA2B | |
| SCHEMBL19951497 | 0.90 | PLK1 (0.34) | IGF1RPLK1HTR1AADRA2AADRA2B | |
| SCHEMBL4272407 | 0.90 | PLK1 (0.34) | IGF1RPLK1HTR1AADRA2AADRA2B | |
| SCHEMBL4264314 | 0.90 | PLK1 (0.34) | IGF1RPLK1HTR1AADRA2AADRA2B | |
| SCHEMBL2198389 | 0.90 | PLK1 (0.34) | IGF1RPLK1HTR1AADRA2AADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114942-B1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | MSD KK (JP) | 2012-10-31 | — | — | EP | claimed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | claimed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | claimed |
| EP-2114942-B1 | NOVEL AMINOPYRIMIDINE DERIVATIVES AS PLK1 INHIBITORS | MSD KK (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7977336-B2 | Aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO. LTD (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305081-A1 | Novel aminopyrimidine derivatives as PLK1 inhibitors | PLK1, AURKA, CDK1 | IGF1R 812/4885PLK1 1/4885ADRB2 3707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.